ArticleBlood cancer journal2022
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 30 citations in OpenAlex.
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.The New England journal of medicine · 2022Trial
- Article
- Validation of the new IMS/IMWG consensus genomic staging (CGS) of high-risk multiple myeloma (HRMM) in a contemporary cohort of 1209 patients.HemaSphere · 2026Article
- Application of Fluorescence in situ Hybridization in Malignant Hemopathies: First Experience from Albania.Balkan journal of medical genetics : BJMG · 2026Article
- Genetic and clinical insights into the coexistence of multiple myeloma and diffuse large B cell lymphoma from a case report and systematic review with bioinformatics analysis.Discover oncology · 2026Article
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- Outcomes of Double-Hit and Single High-Risk Cytogenetic Newly Diagnosed Myeloma in Transplant-Eligible Patients.Current oncology (Toronto, Ont.) · 2026Article
- Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma.Biomedicines · 2026Article
- A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias.Blood cancer journal · 2026Article
- The Role of Genomics in the Development and Treatment of Multiple Myeloma: Understanding the Challenges and Opportunities.OncoTargets and therapy · 2026Review
- Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies.Molecular medicine (Cambridge, Mass.) · 2025Article
- Characterization of cytogenetic abnormalities in Lebanese multiple myeloma patients.BMC cancer · 2025Article
- Multiple Myeloma Laboratory Diagnostics Made Simple: Practical Insights and Key Recommendations.Journal of clinical medicine · 2025Review
- Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.Haematologica · 2025Article
- Individualized dynamic risk assessment and treatment selection for multiple myeloma.British journal of cancer · 2025Article
- Targeting transcription-replication conflicts using G-quadruplexes stabilizers in multiple myeloma.Blood neoplasia · 2025Article
- Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapy synergy between CARM1 inhibition and IMiDs.Molecular therapy. Oncology · 2025Article
- Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma.Blood neoplasia · 2025Article
- Reconstructing tumor clonal heterogeneity and evolutionary relationships based on tumor DNA sequencing data.Briefings in bioinformatics · 2024Article
- Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma.Blood cancer journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrations on TP53, either as deletions of chromosome 17p (del17p) or mutations, are associated with poor outcome in multiple myeloma (MM), but conventional detection methods currently in use underestimate their incidence, hindering an optimal risk assessment and prognostication of MM patients. We have investigated the altered status of TP53 gene by SNPs array and sequencing techniques in a homogenous cohort of 143 newly diagnosed MM patients, evaluated both at diagnosis and at first relapse: single-hit on TP53 gene, either deletion or mutation, detected both at clonal and sub-clonal level, had a minor effect on outcomes. Conversely, the coexistence of both TP53 deletion and mutation, which defined the so-called double-hit patients, was associated with the worst clinical outcome (PFS: HR 3.34 [95% CI: 1.37-8.12] p = 0.008; OS: HR 3.47 [95% CI: 1.18-10.24] p = 0.02). Moreover, the analysis of longitudinal samples pointed out that TP53 allelic status might increase during the disease course. Notably, the acquisition of TP53 alterations at relapse dramatically worsened the clinical course of patients. Overall, our analyses showed these techniques to be highly sensitive to identify TP53 aberrations at sub-clonal level, emphasizing the poor prognosis associated with double-hit MM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.